Journal Home > Volume 11 , Issue 6
Food Science and Human Wellness 2022, 11(6): 1544-1554 https://doi.org/10.1016/j.fshw.2022.06.012
Research Article | Open Access | Issue | Published: 18 July 2022

A soy glycinin derived octapeptide protects against MCD diet induced non-alcoholic fatty liver disease in mice

Show Author's Information Peng Ma,  Rongrong Huang,  Yu Ou( )
School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China

Peer review under responsibility of KeAi Communications Co., Ltd.

Keywords:
HepG2 cells, Soy glycinin derived octapeptide (SGP8), Non-alcoholic fatty liver disease (NAFLD), Methionine-choline deficient (MCD), SIRT1/AMPK pathway
Cite this article:
Ma P, Huang R, Ou Y. A soy glycinin derived octapeptide protects against MCD diet induced non-alcoholic fatty liver disease in mice. Food Science and Human Wellness, 2022, 11(6): 1544-1554. https://doi.org/10.1016/j.fshw.2022.06.012
Download citation
EndNote(RIS)
BibTeX

380

Views

30

Downloads

Citations

3

Crossref

3

WoS

3

Scopus

0

CSCD

Abstract Full text About this article

Soy glycinin derived octapeptide (SGP8) is a peptide obtained from degradation of the soy glycinin, whose amino acid sequence is IAVPGEVA. To determine the effect of SGP8 on non-alcoholic fatty liver disease (NAFLD), steatosis HepG2 cells were induced by 1 mmol/L free fatty acid (FFA) and C57BL/6J mice were fed with methionine-choline deficient (MCD) diet for 3 weeks to establish NAFLD model. The results of oil red O staining and total cholesterol (TC)/triglyceride (TG) contents showed that SGP8 could significantly reduce the lipid content of steatosis HepG2 cells. In vivo, SGP8 lowered plasma alanine aminotransferase (ALT) and low density lipoprotein (LDL) content, normalized hepatic superoxide dismutase (SOD) and malondialdehyde (MDA) production, and reduced the severity of liver inflammation. The results of Western blotting showed that SGP8 increased expression of Sirtuin-1 (SIRT1) and phosphorylation level of AMP activated protein kinase (AMPK) in hepatocytes. Through activation of SIRT1/AMPK pathway, SGP8 downregulated the expression of sterol regulatory element binding protein 1c (SREBP-1c) and its target genes ACC and FAS expression levels, and increased the phosphorylation level of acetyl CoA carboxylase (ACC). Furthermore, SGP8 also upregulated the expression of transcription factor peroxisome proliferator activated receptor α (PPARα), which was regulated by SIRT1/AMPK pathway, and its target gene CPT1 level. In conclusion, SGP8 might improve NAFLD by activating the SIRT1/AMPK pathway. Our data suggest that SGP8 may act as a novel and potent therapeutic agent against NAFLD.


menu
Abstract
Full text
Outline
About this article

A soy glycinin derived octapeptide protects against MCD diet induced non-alcoholic fatty liver disease in mice

Show Author's information Peng Ma, Rongrong Huang, Yu Ou( )
School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China

Peer review under responsibility of KeAi Communications Co., Ltd.

Abstract

Soy glycinin derived octapeptide (SGP8) is a peptide obtained from degradation of the soy glycinin, whose amino acid sequence is IAVPGEVA. To determine the effect of SGP8 on non-alcoholic fatty liver disease (NAFLD), steatosis HepG2 cells were induced by 1 mmol/L free fatty acid (FFA) and C57BL/6J mice were fed with methionine-choline deficient (MCD) diet for 3 weeks to establish NAFLD model. The results of oil red O staining and total cholesterol (TC)/triglyceride (TG) contents showed that SGP8 could significantly reduce the lipid content of steatosis HepG2 cells. In vivo, SGP8 lowered plasma alanine aminotransferase (ALT) and low density lipoprotein (LDL) content, normalized hepatic superoxide dismutase (SOD) and malondialdehyde (MDA) production, and reduced the severity of liver inflammation. The results of Western blotting showed that SGP8 increased expression of Sirtuin-1 (SIRT1) and phosphorylation level of AMP activated protein kinase (AMPK) in hepatocytes. Through activation of SIRT1/AMPK pathway, SGP8 downregulated the expression of sterol regulatory element binding protein 1c (SREBP-1c) and its target genes ACC and FAS expression levels, and increased the phosphorylation level of acetyl CoA carboxylase (ACC). Furthermore, SGP8 also upregulated the expression of transcription factor peroxisome proliferator activated receptor α (PPARα), which was regulated by SIRT1/AMPK pathway, and its target gene CPT1 level. In conclusion, SGP8 might improve NAFLD by activating the SIRT1/AMPK pathway. Our data suggest that SGP8 may act as a novel and potent therapeutic agent against NAFLD.

Keywords: HepG2 cells, Soy glycinin derived octapeptide (SGP8), Non-alcoholic fatty liver disease (NAFLD), Methionine-choline deficient (MCD), SIRT1/AMPK pathway

References(58)

[1]

R. Loomba, A.J. Sanyal, The global NAFLD epidemic, Nat. Rev. Gastroenterol. Hepatol. 10 (2013) 686-690. https://doi.org/10.1038/nrgastro.2013.171.
DOI Google Scholar
[2]

W.L. Shapiro, E.L. Yu, J.C. Arin, et al., Clinical practice approach to nonalcoholic fatty liver disease by pediatric gastroenterologists in the United States, J. Pediatr. Gastroenterol. Nutr. 68 (2019) 182-189. https://doi.org/10.1097/mpg.0000000000002194.
DOI Google Scholar
[3]

C.A. Onyekwere, A.O. Ogbera, B.O. Balogun, Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community, Ann. Hepatol. 10 (2011) 119-124. https://doi.org/10.1016/S1665-2681(19)31559-5.
DOI Google Scholar
[4]

L. Caballería, G. Pera, M.A. Auladell, et al., Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain, Eur. J. Gastroenterol. Hepatol. 22 (2010) 24-32. https://doi.org/10.1097/MEG.0b013e32832fcdf0.
DOI Google Scholar
[5]

C. Xu, C. Yu, H. Ma, et al., Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study, Am. J. Gastroenterol. 108 (2013) 1299-1304. https://doi.org/10.1038/ajg.2013.104.
DOI Google Scholar
[6]

X. Hou, S. Xu, K.A. Maitland-Toolan, et al., SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase, J. Biol. Chem. 283 (2008) 20015-20026. https://doi.org/10.1074/jbc.M802187200.
DOI Google Scholar
[7]

L. Fu, F. Li, A. Bruckbauer, et al., Interaction between leucine and phosphodiesterase 5 inhibition in modulating insulin sensitivity and lipid metabolism, Diabetes Metab. Syndr. Obes. 8 (2015) 227-239. https://doi.org/10.2147/dmso.S82338.
DOI Google Scholar
[8]

D.G. Hardie, F.A. Ross, S.A. Hawley, AMPK: a nutrient and energy sensor that maintains energy homeostasis, Nat. Rev. Mol. Cell Biol. 13 (2012) 251-262. https://doi.org/10.1038/nrm3311.
DOI Google Scholar
[9]

Y. Zhang, S. Li, W. Donelan, et al., Angiopoietin-like protein 8 (betatrophin) is a stress-response protein that down-regulates expression of adipocyte triglyceride lipase, Biochim. Biophys. Acta. 1861 (2016) 130-137. https://doi.org/10.1016/j.bbalip.2015.11.003.
DOI Google Scholar
[10]

M. Janevski, S. Ratnayake, S. Siljanovski, et al., Fructose containing sugars modulate mRNA of lipogenic genes ACC and FAS and protein levels of transcription factors ChREBP and SREBPIc with no effect on body weight or liver fat, Food Funct. 3 (2011) 141-149. https://doi.org/10.1039/c1fo10111k.
DOI Google Scholar
[11]

C. Zhang, X. Chen, R.M. Zhu, et al., Endoplasmic reticulum stress is involved in hepatic SREBP-1c activation and lipid accumulation in fructose-fed mice, Toxicol. Lett. 212 (2012) 229-240. https://doi.org/10.1016/j.toxlet.2012.06.002.
DOI Google Scholar
[12]

Z. Ren, Z. Xie, D. Cao, et al., C-Phycocyanin inhibits hepatic gluconeogenesis and increases glycogen synthesis via activating Akt and AMPK in insulin resistance hepatocytes, Food Funct. 9 (2018) 2829-2839. https://doi.org/10.1039/c8fo00257f.
DOI Google Scholar
[13]

M. Zang, A. Zuccollo, X. Hou, et al., AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells, J. Biol. Chem. 279 (2004) 47898-47905. https://doi.org/10.1074/jbc.M408149200.
DOI Google Scholar
[14]

F. Jiang, Z. Zhang, Y. Zhang, et al., L-carnitine ameliorates the liver inflammatory response by regulating carnitine palmitoyltransferase I-dependent PPARγ signaling, Mol. Med. Rep. 13 (2016) 1320-1328. https://doi.org/10.3892/mmr.2015.4639.
DOI Google Scholar
[15]

G. Pascual, A.L. Fong, S. Ogawa, et al., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ, Nature 437 (2005) 759-763. https://doi.org/10.1038/nature03988.
DOI Google Scholar
[16]

A.K.S. Silva, C.A. Peixoto, Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation, Cell Mol. Life. Sci. 75 (2018) 2951-2961. https://doi.org/10.1007/s00018-018-2838-4.
DOI Google Scholar
[17]

C.J. Villanueva, P. Tontonoz, Licensing PPARγ to work in macrophages, Immunity. 33 (2010) 647-649. https://doi.org/10.1016/j.immuni.2010.11.017.
DOI Google Scholar
[18]

A. Mahzari, S. Li, X. Zhou, et al., Matrine protects against MCD-induced development of NASH via upregulating HSP72 and downregulating mTOR in a manner distinctive from metformin, Front. Pharmacol. 10 (2019) 405. https://doi.org/10.3389/fphar.2019.00405.
DOI Google Scholar
[19]

X.L. Liu, Y.N. Ming, J.Y. Zhang, et al., Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes, Exp. Mol. Med. 49 (2017) e283. https://doi.org/10.1038/emm.2016.123.
DOI Google Scholar
[20]

Q.M. Anstee, R.D. Goldin, Mouse models in non-alcoholic fatty liver disease and steatohepatitis research, Int. J. Exp. Pathol. 87 (2006) 1-16. https://doi.org/10.1111/j.0959-9673.2006.00465.x.
DOI Google Scholar
[21]

R. Kumar, S. Mohan, Non-alcoholic fatty liver disease in lean subjects: characteristics and implications, J. Clin. Transl. Hepatol. 5 (2017) 216-223. https://doi.org/10.14218/jcth.2016.00068.
DOI Google Scholar
[22]

K.M. Schneider, A. Mohs, K. Kilic, et al., Intestinal microbiota protects against MCD diet-induced steatohepatitis, Int. J. Mol. Sci. 20(2) (2019) 308. https://doi.org/10.3390/ijms20020308.
DOI Google Scholar
[23]

M.V. Machado, G.A. Michelotti, G. Xie, et al., Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease, PLoS ONE 10 (2015) e0127991. https://doi.org/10.1371/journal.pone.0127991.
DOI Google Scholar
[24]

Z.M. Younossi, M. Stepanova, F. Negro, et al., Nonalcoholic fatty liver disease in lean individuals in the United States, Medicine (Baltimore) 91 (2012) 319-327. https://doi.org/10.1097/MD.0b013e3182779d49.
DOI Google Scholar
[25]

H. Korhonen, A. Pihlanto, Bioactive peptides: production and functionality, Int. Dairy J. 16 (2006) 945-960. https://doi.org/10.1016/j.idairyj.2005.10.012.
DOI Google Scholar
[26]
L. Mora, M. Gallego, M.C. Aristoy, et al., 12-Bioactive peptides, in: F.J. Barba, J.M.A. Saraiva, G. Cravotto, et al. (Eds. ), Innovative Thermal and Non-thermal Processing, Bioaccessibility and Bioavailability of Nutrients and Bioactive Compounds, Woodhead Publishing, 2019, pp. 333-345. https://doi.org/10.1016/B978-0-12-814174-8.00012-3.
DOI
[27]

C. Lammi, C. Zanoni, A. Arnoldi, IAVPGEVA, IAVPTGVA, and LPYP, three peptides from soy glycinin modulates cholesterol metabolism in HepG2 cells through the activation of the LDLR-SREBP2 pathway, J. Funct. Foods 14 (2015) 469-478. https://doi.org/10.1016/j.jff.2015.02.021.
DOI Google Scholar
[28]

C. Lammi, C. Zanoni, A. Arnoldi, Three peptides from soy glycinin modulate glucose metabolism in human hepatic HepG2 cells, Int. J. Mol. Sci. 16 (2015) 27362-27370. https://doi.org/10.3390/ijms161126029.
DOI Google Scholar
[29]

F. Li, Y. Yang, L. Yang, et al., Resveratrol alleviates FFA and CCl4 induced apoptosis in HepG2 cells via restoring endoplasmic reticulum stress, Oncotarget 8 (2017) 43799-43809. https://doi.org/10.18632/oncotarget.16460.
DOI Google Scholar
[30]

Y.L. Liu, L.C. Lin, Y.T. Tung, et al., Rhododendron oldhamii leaf extract improves fatty liver syndrome by increasing lipid oxidation and decreasing the lipogenesis pathway in mice, Int. J. Med. Sci. 14 (2017) 862-870. https://doi.org/10.7150/ijms.19553.
DOI Google Scholar
[31]

K.J. Oh, J. Park, S.Y. Lee, et al., A typical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism, Am. J. Physiol. Endocrinol. Metab. 300 (2011) E624-E632. https://doi.org/10.1152/ajpendo.00502.2010.
DOI Google Scholar
[32]

A.R. Lee, S.N. Han, Pinolenic acid downregulates lipid anabolic pathway in HepG2 cells, Lipids 51 (2016) 847-855. https://doi.org/10.1007/s11745-016-4149-6.
DOI Google Scholar
[33]

N. Gao, X. Qu, J. Yan, et al., L-FABP T94A decreased fatty acid uptake and altered hepatic triglyceride and cholesterol accumulation in Chang liver cells stably transfected with L-FABP, Mol. Cell. Biochem. 345 (2010) 207-214. https://doi.org/10.1007/s11010-010-0574-7.
DOI Google Scholar
[34]

S. Del Guerra, M. Bugliani, V. D'Aleo, et al., G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids, Nutr. Metab. Cardiovasc. Dis. 20 (2010) 22-25. https://doi.org/10.1016/j.numecd.2009.02.008.
DOI Google Scholar
[35]

Y. Zhang, M.L. Chen, Y. Zhou, et al., Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway, Mol. Nutr. Food. Res. 59 (2015) 1443-1457. https://doi.org/10.1002/mnfr.201500016.
DOI Google Scholar
[36]

P. Nguyen, V. Leray, M. Diez, et al., Liver lipid metabolism, J. Anim. Physiol. Anim. Nutr (Berl). 92 (2008) 272-283. https://doi.org/10.1111/j.1439-0396.2007.00752.x.
DOI Google Scholar
[37]

Y. Wang, J. Viscarra, S.J. Kim, et al., Transcriptional regulation of hepatic lipogenesis, Nat. Rev. Mol. Cell Biol. 16 (2015) 678-689. https://doi.org/10.1038/nrm4074.
DOI Google Scholar
[38]

X. Li, H. Chen, Y. Guan, et al., Acetic acid activates the AMP-activated protein kinase signaling pathway to regulate lipid metabolism in bovine hepatocytes, PLoS ONE 8 (2013) e67880. https://doi.org/10.1371/journal.pone.0067880.
DOI Google Scholar
[39]

M. Bajaj, S. Suraamornkul, L.J. Hardies, et al., Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus, Diabetologia 50 (2007) 1723-1731. https://doi.org/10.1007/s00125-007-0698-9.
DOI Google Scholar
[40]

K. Toriguchi, E. Hatano, K. Tanabe, et al., Attenuation of steatohepatitis, fibrosis, and carcinogenesis in mice fed a methionine-choline deficient diet by CCAAT/enhancer-binding protein homologous protein deficiency, J. Gastroenterol. Hepatol. 29 (2014) 1109-1118. https://doi.org/10.1111/jgh.12481.
DOI Google Scholar
[41]

Y.A. Jung, Y.K. Choi, G.S. Jung, et al., Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis, Diabetes Res. Clin. Pract. 105 (2014) 47-57. https://doi.org/10.1016/j.diabres.2014.04.028.
DOI Google Scholar
[42]

L.M. Jiménez-Flores, S. López-Briones, M.H. Macías-Cervantes, et al., A PPARγ, NF-κB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db/db mice liver, Molecules 19 (2014) 8289-8302. https://doi.org/10.3390/molecules19068289.
DOI Google Scholar
[43]

L. Wu, C. Yan, M. Czader, et al., Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis, Blood 119 (2012) 115-126. https://doi.org/10.1182/blood-2011-06-363093.
DOI Google Scholar
[44]

N.L. Price, A.P. Gomes, A.J. Ling, et al., SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function, Cell Metab. 15 (2012) 675-690. https://doi.org/10.1016/j.cmet.2012.04.003.
DOI Google Scholar
[45]

A. Sandoval-Rodriguez, H.C. Monroy-Ramirez, A. Meza-Rios, et al., Pirfenidone is an agonistic ligand for PPARα and improves NASH by activation of SIRT1/LKB1/pAMPK, Hepatol. Commun. 4 (2020) 434-449. https://doi.org/10.1002/hep4.1474.
DOI Google Scholar
[46]

A. Stacchiotti, I. Grossi, R. García-Gómez, et al., Melatonin effects on non-alcoholic fatty liver disease are related to microRNA-34a-5p/Sirt1 axis and autophagy, Cells 8(9) (2019) 1053. https://doi.org/10.3390/cells8091053.
DOI Google Scholar
[47]

N. Ruderman, M. Prentki, AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome, Nat. Rev. Drug. Discov. 3 (2004) 340-351. https://doi.org/10.1038/nrd1344.
DOI Google Scholar
[48]

S.C. Stein, A. Woods, N.A. Jones, et al., The regulation of AMP-activated protein kinase by phosphorylation, Biochem. J. 345(3) (2000) 437-443. https://doi.org/10.1042/0264-6021:3450437.
DOI Google Scholar
[49]

E. Yuan, X. Duan, L. Xiang, et al., Aged oolong tea reduces high-fat diet-induced fat accumulation and dyslipidemia by regulating the AMPK/ACC signaling pathway, Nutrients 10(2) (2018) 187. https://doi.org/10.3390/nu10020187.
DOI Google Scholar
[50]

E. Robinson, D.J. Grieve, Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease, Pharmacol. Ther. 122 (2009) 246-263. https://doi.org/10.1016/j.pharmthera.2009.03.003.
DOI Google Scholar
[51]

M.S. Rao, J.K. Reddy, PPARα in the pathogenesis of fatty liver disease, Hepatology 40 (2004) 783-786. https://doi.org/10.1002/hep.20453.
DOI Google Scholar
[52]

T. Venäläinen, F. Molnár, C. Oostenbrink, et al., Molecular mechanism of allosteric communication in the human PPARα-RXRα heterodimer, Proteins 78 (2010) 873-887. https://doi.org/10.1002/prot.22613.
DOI Google Scholar
[53]

J. Mun, S. Kim, H.G. Yoon, et al., Water extract of Curcuma longa L. ameliorates non-alcoholic fatty liver disease, Nutrients 11(10) (2019) 2536. https://doi.org/10.3390/nu11102536.
DOI Google Scholar
[54]

R.H. Wong, I. Chang, C.S. Hudak, et al., A role of DNA-PK for the metabolic gene regulation in response to insulin, Cell 136 (2009) 1056-1072. https://doi.org/10.1016/j.cell.2008.12.040.
DOI Google Scholar
[55]

M.J. Griffin, R.H. Wong, N. Pandya, et al., Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter, J. Biol. Chem. 282 (2007) 5453-5467. https://doi.org/10.1074/jbc.M610566200.
DOI Google Scholar
[56]

F. Wen, C. An, X. Wu, et al., MiR-34a regulates mitochondrial content and fat ectopic deposition induced by resistin through the AMPK/PPARα pathway in HepG2 cells, Int. J. Biochem. Cell Biol. 94 (2018) 133-145. https://doi.org/10.1016/j.biocel.2017.11.008.
DOI Google Scholar
[57]

J.W. Lim, J. Dillon, M. Miller, Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis, World J. Gastroenterol. 20 (2014) 8325-8340. https://doi.org/10.3748/wjg.v20.i26.8325.
DOI Google Scholar
[58]

G. Tarantino, V. Citro, D. Capone, Nonalcoholic fatty liver disease: a challenge from mechanisms to therapy, J. Clin. Med. 9(1) (2019) 15. https://doi.org/10.3390/jcm9010015.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 09 November 2020
Revised: 01 February 2021
Accepted: 31 March 2021
Published: 18 July 2022
Issue date: November 2022

Copyright

© 2022 Beijing Academy of Food Sciences.

Acknowledgements

Acknowledgements

This work was funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The authors also thank Dr. Zhu Zhou (City University of New York) for her assistance in reviewing this manuscript and valuable discussion.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return